image stringlengths 20 66 | question stringclasses 16
values | answer stringlengths 3 10.7k |
|---|---|---|
PMC2360260_fig1_21101.jpg | What can you see in this picture? | Assessment of FDG-PET findings. (A) PET scan demonstrates spotty or focal accumulation that is stronger than the uptake in the liver (arrow). (B) PET scan demonstrates focal accumulation in the area of the lower stomach (arrow). (C) PET scan demonstrates no definite accumulation of FDG in the stomach. (D) PET scan demo... |
PMC2360260_fig1_21099.jpg | What can you see in this picture? | Assessment of FDG-PET findings. (A) PET scan demonstrates spotty or focal accumulation that is stronger than the uptake in the liver (arrow). (B) PET scan demonstrates focal accumulation in the area of the lower stomach (arrow). (C) PET scan demonstrates no definite accumulation of FDG in the stomach. (D) PET scan demo... |
PMC2360262_fig3_21103.jpg | Describe the main subject of this image. | (A) Fluorescence-activated cell sorting of transduced cells expressing mitochondrially localised red fluorescent protein. The cells from the gate designated M1 were used in subsequent experiments. (B) Micrographs of the labelled MG63 OS cells. (C) Micrographs of the tumour spheres derived from culture in clotted human ... |
PMC2360262_fig3_21105.jpg | What does this image primarily show? | (A) Fluorescence-activated cell sorting of transduced cells expressing mitochondrially localised red fluorescent protein. The cells from the gate designated M1 were used in subsequent experiments. (B) Micrographs of the labelled MG63 OS cells. (C) Micrographs of the tumour spheres derived from culture in clotted human ... |
PMC2360262_fig3_21106.jpg | What is shown in this image? | (A) Fluorescence-activated cell sorting of transduced cells expressing mitochondrially localised red fluorescent protein. The cells from the gate designated M1 were used in subsequent experiments. (B) Micrographs of the labelled MG63 OS cells. (C) Micrographs of the tumour spheres derived from culture in clotted human ... |
PMC2360266_fig1_21111.jpg | What does this image primarily show? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360266_fig1_21113.jpg | What is the central feature of this picture? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360266_fig1_21108.jpg | What's the most prominent thing you notice in this picture? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360266_fig1_21109.jpg | What does this image primarily show? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360266_fig1_21112.jpg | What can you see in this picture? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360266_fig1_21107.jpg | What stands out most in this visual? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360266_fig1_21110.jpg | What is the core subject represented in this visual? | (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of m... |
PMC2360298_fig4_21118.jpg | What is being portrayed in this visual content? | Expression of VEGF in normal skin. (A) Expression of VEGF determined by staining with antibodies that detect all isoforms (pro- and anti-angiogenic) of VEGF (pan-VEGF antibody). Staining is seen in epidermis (e) and weak diffuse expression in dermis (d) and around blood vessels (bv). Inset is negative control. (B) Expr... |
PMC2360298_fig4_21117.jpg | What is the dominant medical problem in this image? | Expression of VEGF in normal skin. (A) Expression of VEGF determined by staining with antibodies that detect all isoforms (pro- and anti-angiogenic) of VEGF (pan-VEGF antibody). Staining is seen in epidermis (e) and weak diffuse expression in dermis (d) and around blood vessels (bv). Inset is negative control. (B) Expr... |
PMC2360298_fig4_21116.jpg | What is the dominant medical problem in this image? | Expression of VEGF in normal skin. (A) Expression of VEGF determined by staining with antibodies that detect all isoforms (pro- and anti-angiogenic) of VEGF (pan-VEGF antibody). Staining is seen in epidermis (e) and weak diffuse expression in dermis (d) and around blood vessels (bv). Inset is negative control. (B) Expr... |
PMC2360299_fig3_21127.jpg | Describe the main subject of this image. | Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the... |
PMC2360299_fig3_21126.jpg | What is being portrayed in this visual content? | Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the... |
PMC2360299_fig3_21133.jpg | What is the main focus of this visual representation? | Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the... |
PMC2360299_fig3_21132.jpg | What is the central feature of this picture? | Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the... |
PMC2360299_fig3_21128.jpg | What key item or scene is captured in this photo? | Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the... |
PMC2360299_fig3_21131.jpg | What is shown in this image? | Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the... |
PMC2360300_fig4_21123.jpg | What is the central feature of this picture? | (A) HGF-stimulated MDCK/DESC1 cells embebbed in collagen gel form tubular structures. MDCK cell clones stably transfected with control vector or expressing DESC1 were cultured in a type I collagen matrix for 7 days in presence (+) or in absence (−) of 30 ng ml−1 of HGF, and in the presence (+) or absence (−) of 50 μM o... |
PMC2360300_fig4_21122.jpg | What can you see in this picture? | (A) HGF-stimulated MDCK/DESC1 cells embebbed in collagen gel form tubular structures. MDCK cell clones stably transfected with control vector or expressing DESC1 were cultured in a type I collagen matrix for 7 days in presence (+) or in absence (−) of 30 ng ml−1 of HGF, and in the presence (+) or absence (−) of 50 μM o... |
PMC2360300_fig4_21121.jpg | What can you see in this picture? | (A) HGF-stimulated MDCK/DESC1 cells embebbed in collagen gel form tubular structures. MDCK cell clones stably transfected with control vector or expressing DESC1 were cultured in a type I collagen matrix for 7 days in presence (+) or in absence (−) of 30 ng ml−1 of HGF, and in the presence (+) or absence (−) of 50 μM o... |
PMC2360300_fig4_21124.jpg | What does this image primarily show? | (A) HGF-stimulated MDCK/DESC1 cells embebbed in collagen gel form tubular structures. MDCK cell clones stably transfected with control vector or expressing DESC1 were cultured in a type I collagen matrix for 7 days in presence (+) or in absence (−) of 30 ng ml−1 of HGF, and in the presence (+) or absence (−) of 50 μM o... |
PMC2360300_fig4_21120.jpg | Can you identify the primary element in this image? | (A) HGF-stimulated MDCK/DESC1 cells embebbed in collagen gel form tubular structures. MDCK cell clones stably transfected with control vector or expressing DESC1 were cultured in a type I collagen matrix for 7 days in presence (+) or in absence (−) of 30 ng ml−1 of HGF, and in the presence (+) or absence (−) of 50 μM o... |
PMC2360300_fig5_21137.jpg | What is being portrayed in this visual content? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21143.jpg | What does this image primarily show? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21139.jpg | Describe the main subject of this image. | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21140.jpg | What object or scene is depicted here? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21142.jpg | What can you see in this picture? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21135.jpg | What is the principal component of this image? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21141.jpg | What is the main focus of this visual representation? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21134.jpg | What is the dominant medical problem in this image? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360300_fig5_21144.jpg | What is the central feature of this picture? | DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B) (a–d) IHC in kidney. (a) Norm... |
PMC2360308_fig5_21145.jpg | What is shown in this image? | Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible infiltration of CD45+ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12 (C) or Neuro-IL2/IL12 (E) with are... |
PMC2360308_fig5_21149.jpg | What is being portrayed in this visual content? | Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible infiltration of CD45+ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12 (C) or Neuro-IL2/IL12 (E) with are... |
PMC2360308_fig5_21148.jpg | What can you see in this picture? | Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible infiltration of CD45+ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12 (C) or Neuro-IL2/IL12 (E) with are... |
PMC2360308_fig5_21147.jpg | What is the principal component of this image? | Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible infiltration of CD45+ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12 (C) or Neuro-IL2/IL12 (E) with are... |
PMC2360308_fig5_21146.jpg | What is the central feature of this picture? | Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible infiltration of CD45+ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12 (C) or Neuro-IL2/IL12 (E) with are... |
PMC2360308_fig5_21150.jpg | What does this image primarily show? | Tumour histology and immunohistochemistry. Mice vaccinated with RPMI showed well vascularised tumours (black arrow) (A) and negligible infiltration of CD45+ leukocytes (B). Tumours showed much reduced vascularity compared to RPMI-treated controls following vaccination with AJ-IL2/IL12 (C) or Neuro-IL2/IL12 (E) with are... |
PMC2360315_fig2_21151.jpg | Describe the main subject of this image. | Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad-2 staining (B). Inserts B1 and B2 show nuclear localisation (arrowheads) of p-smad-2 in the myofibroblasts and mal... |
PMC2360315_fig2_21153.jpg | What's the most prominent thing you notice in this picture? | Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad-2 staining (B). Inserts B1 and B2 show nuclear localisation (arrowheads) of p-smad-2 in the myofibroblasts and mal... |
PMC2360315_fig2_21157.jpg | What key item or scene is captured in this photo? | Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad-2 staining (B). Inserts B1 and B2 show nuclear localisation (arrowheads) of p-smad-2 in the myofibroblasts and mal... |
PMC2360315_fig2_21156.jpg | What is the principal component of this image? | Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad-2 staining (B). Inserts B1 and B2 show nuclear localisation (arrowheads) of p-smad-2 in the myofibroblasts and mal... |
PMC2360315_fig2_21154.jpg | What is being portrayed in this visual content? | Cellular localisation of active TGF-β1 in gastric cancer. Immunohistochemical staining of gastric carcinomas (sequential frozen sections). Staining pattern for active TGF-β1 (A) corresponds to phospho-smad-2 staining (B). Inserts B1 and B2 show nuclear localisation (arrowheads) of p-smad-2 in the myofibroblasts and mal... |
PMC2360315_fig3_21163.jpg | What stands out most in this visual? | Total TGF-β and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-2 (B, insert × 400). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1; D, p-smad-2, insert × 400).... |
PMC2360315_fig3_21164.jpg | What object or scene is depicted here? | Total TGF-β and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-2 (B, insert × 400). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1; D, p-smad-2, insert × 400).... |
PMC2360315_fig3_21161.jpg | What object or scene is depicted here? | Total TGF-β and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-2 (B, insert × 400). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1; D, p-smad-2, insert × 400).... |
PMC2360315_fig3_21159.jpg | What stands out most in this visual? | Total TGF-β and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-2 (B, insert × 400). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1; D, p-smad-2, insert × 400).... |
PMC2360315_fig3_21158.jpg | What can you see in this picture? | Total TGF-β and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-2 (B, insert × 400). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1; D, p-smad-2, insert × 400).... |
PMC2360315_fig3_21162.jpg | What key item or scene is captured in this photo? | Total TGF-β and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining for total TGF-β (A) and almost no staining for p-smad-2 (B, insert × 400). Both are strongly increased in corresponding tumour tissue (C, total TGF-β1; D, p-smad-2, insert × 400).... |
PMC2360323_fig5_21171.jpg | What does this image primarily show? | Topographic analysis of the invasive front of SCLC using phosphoantibody IHC. (A) Topographic role of p-MET and phosphoproteins with pTyr activation. (B) Overexpression of c-MET along the SCLC invasive tumour front, × 10. Inset: × 4. (C) Overexpression of HGF in SCLC tumour tissue, × 10. Inset: × 4. (D) Topographic rol... |
PMC2360323_fig5_21170.jpg | What is the main focus of this visual representation? | Topographic analysis of the invasive front of SCLC using phosphoantibody IHC. (A) Topographic role of p-MET and phosphoproteins with pTyr activation. (B) Overexpression of c-MET along the SCLC invasive tumour front, × 10. Inset: × 4. (C) Overexpression of HGF in SCLC tumour tissue, × 10. Inset: × 4. (D) Topographic rol... |
PMC2360323_fig5_21167.jpg | What is shown in this image? | Topographic analysis of the invasive front of SCLC using phosphoantibody IHC. (A) Topographic role of p-MET and phosphoproteins with pTyr activation. (B) Overexpression of c-MET along the SCLC invasive tumour front, × 10. Inset: × 4. (C) Overexpression of HGF in SCLC tumour tissue, × 10. Inset: × 4. (D) Topographic rol... |
PMC2360323_fig5_21165.jpg | What is the focal point of this photograph? | Topographic analysis of the invasive front of SCLC using phosphoantibody IHC. (A) Topographic role of p-MET and phosphoproteins with pTyr activation. (B) Overexpression of c-MET along the SCLC invasive tumour front, × 10. Inset: × 4. (C) Overexpression of HGF in SCLC tumour tissue, × 10. Inset: × 4. (D) Topographic rol... |
PMC2360323_fig5_21172.jpg | What is the principal component of this image? | Topographic analysis of the invasive front of SCLC using phosphoantibody IHC. (A) Topographic role of p-MET and phosphoproteins with pTyr activation. (B) Overexpression of c-MET along the SCLC invasive tumour front, × 10. Inset: × 4. (C) Overexpression of HGF in SCLC tumour tissue, × 10. Inset: × 4. (D) Topographic rol... |
PMC2360333_fig4_21177.jpg | What is the core subject represented in this visual? | MT1 enhances invasion solely through its promotion of matrix degradation; not by affecting cell motility. (A) Degradation of biotinylated collagen I matrices by MT1-transfected SKOV-3 and OVCAR-3 cells after a 24 h incubation. Matrices were not degraded by cells expressing the E240A catalytically inactive MT1 mutant, n... |
PMC2360333_fig4_21173.jpg | What is the main focus of this visual representation? | MT1 enhances invasion solely through its promotion of matrix degradation; not by affecting cell motility. (A) Degradation of biotinylated collagen I matrices by MT1-transfected SKOV-3 and OVCAR-3 cells after a 24 h incubation. Matrices were not degraded by cells expressing the E240A catalytically inactive MT1 mutant, n... |
PMC2360333_fig4_21175.jpg | What is shown in this image? | MT1 enhances invasion solely through its promotion of matrix degradation; not by affecting cell motility. (A) Degradation of biotinylated collagen I matrices by MT1-transfected SKOV-3 and OVCAR-3 cells after a 24 h incubation. Matrices were not degraded by cells expressing the E240A catalytically inactive MT1 mutant, n... |
PMC2360333_fig4_21176.jpg | What key item or scene is captured in this photo? | MT1 enhances invasion solely through its promotion of matrix degradation; not by affecting cell motility. (A) Degradation of biotinylated collagen I matrices by MT1-transfected SKOV-3 and OVCAR-3 cells after a 24 h incubation. Matrices were not degraded by cells expressing the E240A catalytically inactive MT1 mutant, n... |
PMC2360338_fig1_21181.jpg | Describe the main subject of this image. | Mitotic centromere-associated kinesin mRNA expression in clinical samples. (A) RT–PCR analysis of MCAK in gastric cancer (T) and paired normal (N) samples obtained from four patients (patient numbers: MK 18, 22, 137, and 154). Mitotic centromere-associated kinesin mRNA expression was observed in cancer samples, but no ... |
PMC2360338_fig1_21179.jpg | What can you see in this picture? | Mitotic centromere-associated kinesin mRNA expression in clinical samples. (A) RT–PCR analysis of MCAK in gastric cancer (T) and paired normal (N) samples obtained from four patients (patient numbers: MK 18, 22, 137, and 154). Mitotic centromere-associated kinesin mRNA expression was observed in cancer samples, but no ... |
PMC2360342_fig7_21183.jpg | What is being portrayed in this visual content? | EBOECs maintain endothelial cell function. Uptake of acetylated LDL is a method for the identification of functional endothelial cells. EBOECs take up acetylated LDL (left) and form vascular tubes in culture (right). Images are representative of triplicate slides (LDL uptake) or wells (vascular tubes). |
PMC2360354_fig3_21187.jpg | What is the main focus of this visual representation? | Cells treated with hypericin (HYP) and excited with 488 nm laser (16 h post-illumination). Detection of fluorescence at (A) 590 nm, (B) 660 nm and (C) 690 nm. The images highlight the highly fluorescent nature of HYP and the ‘spillover’ problem it presents when attempting to isolate its detection in one channel. |
PMC2360354_fig3_21186.jpg | Can you identify the primary element in this image? | Cells treated with hypericin (HYP) and excited with 488 nm laser (16 h post-illumination). Detection of fluorescence at (A) 590 nm, (B) 660 nm and (C) 690 nm. The images highlight the highly fluorescent nature of HYP and the ‘spillover’ problem it presents when attempting to isolate its detection in one channel. |
PMC2360354_fig3_21185.jpg | What can you see in this picture? | Cells treated with hypericin (HYP) and excited with 488 nm laser (16 h post-illumination). Detection of fluorescence at (A) 590 nm, (B) 660 nm and (C) 690 nm. The images highlight the highly fluorescent nature of HYP and the ‘spillover’ problem it presents when attempting to isolate its detection in one channel. |
PMC2360354_fig8_21190.jpg | What is the core subject represented in this visual? | Cells were treated with 2 μg ml−1 MTZ for 20 h followed by 4 h of incubation with 2 μg ml−1 MTZ+2 μM HYP. Specimens were then illuminated for 2 min. Images were taken post-illumination at 4 h for (A) MCF-7/S and (B) MCF-7/R; at 16 h for (C) MCF-7/R; at 24 h for (D) MGHU1/S and (E) MGHU1/R. The white arrow (A) shows nuc... |
PMC2360354_fig8_21192.jpg | What's the most prominent thing you notice in this picture? | Cells were treated with 2 μg ml−1 MTZ for 20 h followed by 4 h of incubation with 2 μg ml−1 MTZ+2 μM HYP. Specimens were then illuminated for 2 min. Images were taken post-illumination at 4 h for (A) MCF-7/S and (B) MCF-7/R; at 16 h for (C) MCF-7/R; at 24 h for (D) MGHU1/S and (E) MGHU1/R. The white arrow (A) shows nuc... |
PMC2360354_fig8_21191.jpg | What is the core subject represented in this visual? | Cells were treated with 2 μg ml−1 MTZ for 20 h followed by 4 h of incubation with 2 μg ml−1 MTZ+2 μM HYP. Specimens were then illuminated for 2 min. Images were taken post-illumination at 4 h for (A) MCF-7/S and (B) MCF-7/R; at 16 h for (C) MCF-7/R; at 24 h for (D) MGHU1/S and (E) MGHU1/R. The white arrow (A) shows nuc... |
PMC2360354_fig8_21189.jpg | What is the main focus of this visual representation? | Cells were treated with 2 μg ml−1 MTZ for 20 h followed by 4 h of incubation with 2 μg ml−1 MTZ+2 μM HYP. Specimens were then illuminated for 2 min. Images were taken post-illumination at 4 h for (A) MCF-7/S and (B) MCF-7/R; at 16 h for (C) MCF-7/R; at 24 h for (D) MGHU1/S and (E) MGHU1/R. The white arrow (A) shows nuc... |
PMC2360358_fig6_21194.jpg | What can you see in this picture? | Cytopathology of T98G cells exposed to vehicle or 17α-AED (10 μM) for 30 h. (A) T98G cultures treated with vehicle are composed of cells with epithelioid morphology; a large, pale staining nucleus with prominent nucleoli. A T98G cell undergoing mitosis (M). (B, C) Numerous cells in the 17α-AED-treated cultures show the... |
PMC2360358_fig6_21195.jpg | What can you see in this picture? | Cytopathology of T98G cells exposed to vehicle or 17α-AED (10 μM) for 30 h. (A) T98G cultures treated with vehicle are composed of cells with epithelioid morphology; a large, pale staining nucleus with prominent nucleoli. A T98G cell undergoing mitosis (M). (B, C) Numerous cells in the 17α-AED-treated cultures show the... |
PMC2360374_fig1_21196.jpg | What is the principal component of this image? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21202.jpg | What is the core subject represented in this visual? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21205.jpg | What is being portrayed in this visual content? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21199.jpg | What stands out most in this visual? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21197.jpg | What can you see in this picture? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21204.jpg | What stands out most in this visual? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21206.jpg | What can you see in this picture? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21200.jpg | What key item or scene is captured in this photo? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21208.jpg | Describe the main subject of this image. | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21207.jpg | What is the core subject represented in this visual? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360374_fig1_21203.jpg | What does this image primarily show? | Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (... |
PMC2360401_fig1_21211.jpg | What is the core subject represented in this visual? | Immunohistochemical patterns of EGFR expression in a carcinomas of an unknown primary site (CUP) specimen showing strong EGFR immunostaining (magnification × 400). |
PMC2360401_fig2_21209.jpg | What is the dominant medical problem in this image? | Immunohistochemical patterns of Her-2/neu expression in a carcinomas of an unknown primary site (CUP) specimen showing strong HER-2/neu immunostaining (magnification × 400). |
PMC2360401_fig3_21210.jpg | What key item or scene is captured in this photo? | Immunohistochemical patterns of c-Kit expression in a carcinomas of an unknown primary site (CUP) specimen showing strong c-Kit immunostaining (magnification × 400). |
PMC2360404_fig1_21213.jpg | What is the principal component of this image? | Immunostaining of mast cells with monoclonal antibody against mast cell-specific tryptase in prostate biopsy specimens. (A) A case with high-level mast cell infiltration. (B) A case with low-level mast cell infiltration. Bar, 20 μm. |
PMC2360416_fig1_21218.jpg | What is the central feature of this picture? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig1_21219.jpg | What is being portrayed in this visual content? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig1_21220.jpg | What object or scene is depicted here? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig1_21216.jpg | What stands out most in this visual? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig1_21221.jpg | What is the principal component of this image? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig1_21222.jpg | What does this image primarily show? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig1_21215.jpg | What can you see in this picture? | Immunofluorescence staining of cells using anti-MUC1 antibody (CD227). (A, B) DIC microscopy images show clusters of Capan-1 and HPAF-II cell lines and (C) DIC images show U-87 MG (negative control) cells without clustering. (D, E, F) Fluorescence microscopy images show relative extent of FITC-conjugated anti-MUC1 anti... |
PMC2360416_fig2_21227.jpg | What is the principal component of this image? | Determining the maximum non-toxic concentration of benzyl-α-GalNAc. (A) Percent cell viability of Capan-1 (○), HPAF-II (▪) and U-87 MG (Δ) cells was determined after exposing 1 × 104 cells per ml to different concentrations of benzyl-α-GalNAc for 72 h. Percent viability of Capan-1 cells was significantly lower at conce... |
PMC2360416_fig2_21226.jpg | What does this image primarily show? | Determining the maximum non-toxic concentration of benzyl-α-GalNAc. (A) Percent cell viability of Capan-1 (○), HPAF-II (▪) and U-87 MG (Δ) cells was determined after exposing 1 × 104 cells per ml to different concentrations of benzyl-α-GalNAc for 72 h. Percent viability of Capan-1 cells was significantly lower at conce... |
PMC2360416_fig2_21228.jpg | What is the core subject represented in this visual? | Determining the maximum non-toxic concentration of benzyl-α-GalNAc. (A) Percent cell viability of Capan-1 (○), HPAF-II (▪) and U-87 MG (Δ) cells was determined after exposing 1 × 104 cells per ml to different concentrations of benzyl-α-GalNAc for 72 h. Percent viability of Capan-1 cells was significantly lower at conce... |
PMC2360416_fig2_21229.jpg | What is the core subject represented in this visual? | Determining the maximum non-toxic concentration of benzyl-α-GalNAc. (A) Percent cell viability of Capan-1 (○), HPAF-II (▪) and U-87 MG (Δ) cells was determined after exposing 1 × 104 cells per ml to different concentrations of benzyl-α-GalNAc for 72 h. Percent viability of Capan-1 cells was significantly lower at conce... |
PMC2360416_fig2_21230.jpg | Can you identify the primary element in this image? | Determining the maximum non-toxic concentration of benzyl-α-GalNAc. (A) Percent cell viability of Capan-1 (○), HPAF-II (▪) and U-87 MG (Δ) cells was determined after exposing 1 × 104 cells per ml to different concentrations of benzyl-α-GalNAc for 72 h. Percent viability of Capan-1 cells was significantly lower at conce... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.